Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Fusion protein capable of inhibiting tumor neovascularization and production technology thereof

A technology for tumor neovascularization and fusion proteins, which is applied in the field of long-acting recombinant proteins, can solve the problems of limiting therapeutic effects, and achieve the effects of convenient downstream purification, process-based production, and high levels of secreted proteins

Inactive Publication Date: 2012-02-22
HUAQIAO UNIVERSITY
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] Since protein drugs are quickly cleared in the body, patients must take frequent medications to keep the drug concentration within the therapeutic window, limiting its therapeutic effect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Fusion protein capable of inhibiting tumor neovascularization and production technology thereof
  • Fusion protein capable of inhibiting tumor neovascularization and production technology thereof
  • Fusion protein capable of inhibiting tumor neovascularization and production technology thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0030] 1. Construction of expression vector

[0031] According to the NCBI reference sequence of human Kal cDNA (Reference Sequence: NM_006215.2) and the NCBI reference sequence of hCGβ chain (Reference Sequence: NM_033378.1), we commissioned Dalian Bao Biological Company to fully synthesize the fusion sequence of human Kal cDNA and hCGβ-CTP ( figure 1 , see the sequence listing SEQ ID No.1). hCGβ-CTP is the 118th-145th amino acid sequence of the C-terminus of hCGβ chain. Hind III and EcoR I restriction sites were introduced at the 5' and 3' ends of the fusion sequence, respectively, in order to construct eukaryotic expression vectors.

[0032] The fusion sequence containing the full-length Kal cDNA sequence and the hCGβ-CTP sequence was subjected to HindIII and EcoRI double digestion, and connected to the HindIII and EcoRI double restriction site of the pcDNA3.1 plasmid produced by Invitrogen to obtain pcDNA3.1-LA- Kal(28) expression plasmid.

[0033] The pcDNA3.1-LA-Kal(...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a fusion protein capable of inhibiting tumor neovascularization and a production technology thereof. The fusion protein contains all sequences of mature human kallistatin and a carboxyl terminal peptide (CTP) of a human chorionic gonadotropin beta (hCGbeta) chain. The LA-Kal protein is expressed by adopting high-level secretion of CHO cells. Because the secreted protein level is high, the downstream purification is very convenient; and the purity of the protein can reach over 98 percent by two-step chromatography, so the protein is very convenient for process production.

Description

technical field [0001] The present invention relates to molecular pharmacology, biotechnology and disease prevention and treatment, specifically adopts Chinese hamster ovary cell (CHO) to produce a kind of long-acting recombination protein of anti-tumor neovascularization, and this protein is human Kallistatin (Kal) and human chorion A fusion protein (LA-Kal, long acting Kal) of the carboxy-terminal peptide (CTP) of the beta chain of gonadotropin (hCG). The in vivo half-life of the fusion protein LA-Kal is significantly increased compared with the wild-type Kal, which improves the anti-tumor efficacy. Background technique [0002] At present, malignant tumors have become the leading fatal diseases in developed countries and regions. Although surgery, radiotherapy and chemotherapy are still being developed as conventional treatments, due to their inherent limitations, their curative effect has basically reached the limit, so there is an urgent need to develop new treatments....

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K19/00C07K1/36C07K1/30C07K1/22C07K1/20C12P21/02
Inventor 刁勇黄晓平
Owner HUAQIAO UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com